Viatris Inc. and Perrigo Company plc: SG&A Spending Patterns Compared

SG&A Spending Patterns: Viatris Inc. vs. Perrigo Company plc

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, Viatris Inc. and Perrigo Company plc have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. consistently outpaced Perrigo in SG&A spending, with a notable 210% increase from 2014 to 2023. In contrast, Perrigo's SG&A expenses grew by approximately 89% during the same period.

Key Insights

• Viatris Inc.: Peaked in 2023 with SG&A expenses reaching nearly 4.65 billion, reflecting a strategic focus on expansion and market penetration.
• Perrigo Company plc: Demonstrated a more conservative growth, with expenses peaking at 1.27 billion in 2023, indicating a focus on cost efficiency.

These trends highlight the diverse strategies employed by these companies in navigating the competitive pharmaceutical market.